Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WSD0922-FU in GBM, AA, and NSCLC CNS Metastases
NCT04197934Phase 1Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Dec 2019
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of WSD-0922 in glioblastoma (GBM), anaplastic astrocytoma (AA) and non-small cell lung cancer (NSCLC) (4 arms), sponsored by Mayo Clinic. Primary endpoint: Recommended phase 2 dose up to 28 days. Started Dec 2019; status: active, not recruiting.
02
Drugs
WSD-0922
03
Conditions
glioblastoma (GBM)anaplastic astrocytoma (AA)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04197934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04197934.